Jonathan Chang
Stock Analyst at Leerink Partners
(0.61)
# 4,088
Out of 5,182 analysts
79
Total ratings
30.56%
Success rate
-21.27%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Chang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines | Maintains: Outperform | $147 → $171 | $135.30 | +26.39% | 6 | Apr 22, 2026 | |
| REPL Replimune Group | Downgrades: Market Perform | $11 → $2 | $2.42 | -17.36% | 12 | Apr 13, 2026 | |
| ZLAB Zai Lab | Maintains: Outperform | $73 → $75 | $22.77 | +229.38% | 9 | Jun 30, 2025 | |
| GMAB Genmab | Upgrades: Outperform | $27 | $26.87 | +0.48% | 10 | Feb 13, 2025 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $74 | $29.30 | +152.56% | 1 | Apr 29, 2024 | |
| NBTX Nanobiotix | Initiates: Outperform | $11 | $33.58 | -67.24% | 1 | Dec 8, 2023 | |
| NVCR NovoCure | Initiates: Outperform | $51 | $12.47 | +308.98% | 1 | Aug 4, 2023 | |
| KPTI Karyopharm Therapeutics | Maintains: Market Perform | $90 → $75 | $8.66 | +766.05% | 12 | Jan 10, 2023 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $48 → $50 | $4.84 | +933.06% | 4 | Aug 22, 2022 | |
| MGNX MacroGenics | Maintains: Outperform | $15 → $12 | $3.19 | +276.18% | 8 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $26 | $11.35 | +129.07% | 5 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $41 → $28 | $9.26 | +202.38% | 3 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 → $53 | $12.98 | +308.32% | 7 | Aug 5, 2021 |
Revolution Medicines
Apr 22, 2026
Maintains: Outperform
Price Target: $147 → $171
Current: $135.30
Upside: +26.39%
Replimune Group
Apr 13, 2026
Downgrades: Market Perform
Price Target: $11 → $2
Current: $2.42
Upside: -17.36%
Zai Lab
Jun 30, 2025
Maintains: Outperform
Price Target: $73 → $75
Current: $22.77
Upside: +229.38%
Genmab
Feb 13, 2025
Upgrades: Outperform
Price Target: $27
Current: $26.87
Upside: +0.48%
Immunocore Holdings
Apr 29, 2024
Initiates: Outperform
Price Target: $74
Current: $29.30
Upside: +152.56%
Nanobiotix
Dec 8, 2023
Initiates: Outperform
Price Target: $11
Current: $33.58
Upside: -67.24%
NovoCure
Aug 4, 2023
Initiates: Outperform
Price Target: $51
Current: $12.47
Upside: +308.98%
Karyopharm Therapeutics
Jan 10, 2023
Maintains: Market Perform
Price Target: $90 → $75
Current: $8.66
Upside: +766.05%
Bicycle Therapeutics
Aug 22, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $4.84
Upside: +933.06%
MacroGenics
Aug 9, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $3.19
Upside: +276.18%
Jun 3, 2022
Maintains: Outperform
Price Target: $25 → $26
Current: $11.35
Upside: +129.07%
Feb 25, 2022
Maintains: Outperform
Price Target: $41 → $28
Current: $9.26
Upside: +202.38%
Aug 5, 2021
Maintains: Outperform
Price Target: $57 → $53
Current: $12.98
Upside: +308.32%